Nebivolol Desensitizes Myofilaments of a Hypertrophic Cardiomyopathy Mouse Model

Overview

Journal Front Physiol

Date 2017 Aug 22

PMID 28824454

Citations 9

Authors

Sabrina Stucker

Nico Kresin

Lucie Carrier

Felix W Friedrich

Affiliations

Soon will be listed here.

Abstract

Hypertrophic cardiomyopathy (HCM) patients often present with diastolic dysfunction and a normal to supranormal systolic function. To counteract this hypercontractility, guideline therapies advocate treatment with beta-adrenoceptor and Ca channel blockers. One well established pathomechanism for the hypercontractile phenotype frequently observed in HCM patients and several HCM mouse models is an increased myofilament Ca sensitivity. Nebivolol, a commonly used beta-adrenoceptor antagonist, has been reported to lower maximal force development and myofilament Ca sensitivity in rabbit and human heart tissues. The aim of this study was to evaluate the effect of nebivolol in cardiac muscle strips of an established HCM mouse model. Furthermore, we investigated actions of nebivolol and epigallocatechin-gallate, which has been shown to desensitize myofilaments for Ca in mouse and human HCM models, in cardiac strips of HCM patients with a mutation in the most frequently mutated HCM gene . Nebivolol effects were tested on contractile parameters and force-Ca relationship of skinned ventricular muscle strips isolated from -targeted knock-in (KI), wild-type (WT) mice and cardiac strips of three HCM patients with mutations. At baseline, KI strips showed no difference in maximal force development compared to WT mouse heart strips. Neither 1 nor 10 μM nebivolol had an effect on maximal force development in both genotypes. 10 μM nebivolol induced myofilament Ca desensitization in WT strips and to a greater extent in KI strips. Neither 1 nor 10 μM nebivolol had an effect on Ca sensitivity in cardiac muscle strips of three HCM patients with mutations, whereas epigallocatechin-gallate induced a right shift in the force-Ca curve. Nebivolol induced a myofilament Ca desensitization in both WT and KI strips, which was more pronounced in KI muscle strips. In human cardiac muscle strips of three HCM patients nebivolol had no effect on myofilament Ca sensitivity.

Citing Articles

Hypertrophic cardiomyopathy: insights into pathophysiology and novel therapeutic strategies from clinical studies.

Olalekan S, Bakare O, Okwute P, Osonuga I, Adeyanju M, Edema V Egypt Heart J. 2025; 77(1):5.

PMID: 39776022 PMC: 11706819. DOI: 10.1186/s43044-024-00600-4.

Pushing the Limits of Medical Management in HCM: A Review of Current Pharmacological Therapy Options.

Statescu C, Enachi S, Ureche C, Tapoi L, Anghel L, Salaru D Int J Mol Sci. 2021; 22(13).

PMID: 34281272 PMC: 8268685. DOI: 10.3390/ijms22137218.

Small Molecules acting on Myofilaments as Treatments for Heart and Skeletal Muscle Diseases.

Alsulami K, Marston S Int J Mol Sci. 2020; 21(24).

PMID: 33339418 PMC: 7767104. DOI: 10.3390/ijms21249599.

Approaches to High-Throughput Analysis of Cardiomyocyte Contractility.

Wright P, Tsui S, Francis A, MacLeod K, Marston S Front Physiol. 2020; 11:612.

PMID: 32733259 PMC: 7362994. DOI: 10.3389/fphys.2020.00612.

Meta-analysis of cardiomyopathy-associated variants in troponin genes identifies loci and intragenic hot spots that are associated with worse clinical outcomes.

Tadros H, Life C, Garcia G, Pirozzi E, Jones E, Datta S J Mol Cell Cardiol. 2020; 142:118-125.

PMID: 32278834 PMC: 7275889. DOI: 10.1016/j.yjmcc.2020.04.005.

References

Lund L, Benson L, Dahlstrom U, Edner M, Friberg L . Association between use of β-blockers and outcomes in patients with heart failure and preserved ejection fraction. JAMA. 2014; 312(19):2008-18. DOI: 10.1001/jama.2014.15241. View

Baudenbacher F, Schober T, Pinto J, Sidorov V, Hilliard F, Solaro R . Myofilament Ca2+ sensitization causes susceptibility to cardiac arrhythmia in mice. J Clin Invest. 2008; 118(12):3893-903. PMC: 2582931. DOI: 10.1172/JCI36642. View

Huke S, Knollmann B . Increased myofilament Ca2+-sensitivity and arrhythmia susceptibility. J Mol Cell Cardiol. 2010; 48(5):824-33. PMC: 2854218. DOI: 10.1016/j.yjmcc.2010.01.011. View

Thottakara T, Friedrich F, Reischmann S, Braumann S, Schlossarek S, Kramer E . The E3 ubiquitin ligase Asb2β is downregulated in a mouse model of hypertrophic cardiomyopathy and targets desmin for proteasomal degradation. J Mol Cell Cardiol. 2015; 87:214-24. DOI: 10.1016/j.yjmcc.2015.08.020. View

Ho C, Charron P, Richard P, Girolami F, Spaendonck-Zwarts K, Pinto Y . Genetic advances in sarcomeric cardiomyopathies: state of the art. Cardiovasc Res. 2015; 105(4):397-408. PMC: 4349164. DOI: 10.1093/cvr/cvv025. View

Elliott P, Andersson B, Arbustini E, Bilinska Z, Cecchi F, Charron P . Classification of the cardiomyopathies: a position statement from the European Society Of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J. 2007; 29(2):270-6. DOI: 10.1093/eurheartj/ehm342. View

Kimura A . Molecular basis of hereditary cardiomyopathy: abnormalities in calcium sensitivity, stretch response, stress response and beyond. J Hum Genet. 2010; 55(2):81-90. DOI: 10.1038/jhg.2009.138. View

Piccini J, Sinner M, Greiner M, Hammill B, Fontes J, Daubert J . Outcomes of Medicare beneficiaries undergoing catheter ablation for atrial fibrillation. Circulation. 2012; 126(18):2200-7. PMC: 3500836. DOI: 10.1161/CIRCULATIONAHA.112.109330. View

Fraysse B, Weinberger F, Bardswell S, Cuello F, Vignier N, Geertz B . Increased myofilament Ca2+ sensitivity and diastolic dysfunction as early consequences of Mybpc3 mutation in heterozygous knock-in mice. J Mol Cell Cardiol. 2012; 52(6):1299-307. PMC: 3370652. DOI: 10.1016/j.yjmcc.2012.03.009. View

10.

Cazorla O, Szilagyi S, Vignier N, Salazar G, Kramer E, Vassort G . Length and protein kinase A modulations of myocytes in cardiac myosin binding protein C-deficient mice. Cardiovasc Res. 2005; 69(2):370-80. DOI: 10.1016/j.cardiores.2005.11.009. View

11.

Tardiff J, Carrier L, Bers D, Poggesi C, Ferrantini C, Coppini R . Targets for therapy in sarcomeric cardiomyopathies. Cardiovasc Res. 2015; 105(4):457-70. PMC: 4402369. DOI: 10.1093/cvr/cvv023. View

12.

Tadano N, Du C, Yumoto F, Morimoto S, Ohta M, Xie M . Biological actions of green tea catechins on cardiac troponin C. Br J Pharmacol. 2010; 161(5):1034-43. PMC: 2998685. DOI: 10.1111/j.1476-5381.2010.00942.x. View

13.

Pohlmann L, Kroger I, Vignier N, Schlossarek S, Kramer E, Coirault C . Cardiac myosin-binding protein C is required for complete relaxation in intact myocytes. Circ Res. 2007; 101(9):928-38. DOI: 10.1161/CIRCRESAHA.107.158774. View

14.

Edes I, Kiss E, Kitada Y, Powers F, Papp J, Kranias E . Effects of Levosimendan, a cardiotonic agent targeted to troponin C, on cardiac function and on phosphorylation and Ca2+ sensitivity of cardiac myofibrils and sarcoplasmic reticulum in guinea pig heart. Circ Res. 1995; 77(1):107-13. DOI: 10.1161/01.res.77.1.107. View

15.

Hill T, Eisenberg E, Greene L . Theoretical model for the cooperative equilibrium binding of myosin subfragment 1 to the actin-troponin-tropomyosin complex. Proc Natl Acad Sci U S A. 1980; 77(6):3186-90. PMC: 349579. DOI: 10.1073/pnas.77.6.3186. View

16.

Stoehr A, Neuber C, Baldauf C, Vollert I, Friedrich F, Flenner F . Automated analysis of contractile force and Ca2+ transients in engineered heart tissue. Am J Physiol Heart Circ Physiol. 2014; 306(9):H1353-63. PMC: 4116534. DOI: 10.1152/ajpheart.00705.2013. View

17.

Janssen P, Zeitz O, Hasenfuss G . Transient and sustained impacts of hydroxyl radicals on sarcoplasmic reticulum function: protective effects of nebivolol. Eur J Pharmacol. 1999; 366(2-3):223-32. DOI: 10.1016/s0014-2999(98)00907-8. View

18.

Janssen P, Zeitz O, Rahman A, Hasenfuss G . Protective role of nebivolol in hydroxyl radical induced injury. J Cardiovasc Pharmacol. 2002; 38 Suppl 3:S17-23. DOI: 10.1097/00005344-200112003-00004. View

19.

Girolami F, Olivotto I, Passerini I, Zachara E, Nistri S, Re F . A molecular screening strategy based on beta-myosin heavy chain, cardiac myosin binding protein C and troponin T genes in Italian patients with hypertrophic cardiomyopathy. J Cardiovasc Med (Hagerstown). 2006; 7(8):601-7. DOI: 10.2459/01.JCM.0000237908.26377.d6. View

20.

Kooij V, Boontje N, Zaremba R, Jaquet K, Dos Remedios C, Stienen G . Protein kinase C alpha and epsilon phosphorylation of troponin and myosin binding protein C reduce Ca2+ sensitivity in human myocardium. Basic Res Cardiol. 2009; 105(2):289-300. PMC: 2807945. DOI: 10.1007/s00395-009-0053-z. View